Argenx (ARGX) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $61.75B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | NL | CEO | Karen Massey |
| IPO Date | 2017-05-18 | CAGR | 76.51% |
| Employees | 1,863 | Website | www.argenx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.03% | Total Yield | 0.03% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $61.93B | P/E | 89.62 | Forward P/E | 22.36 | PEG | 0.09 |
| P/S | 13.2 | P/B | 8.13 | P/CF | 60.94 | P/FCF | 61.15 |
| Sales | $7.76B | Sales 1Y | 140.81% | Sales 3Y | 717.28% | Sales 5Y | 11679.27% |
| EPS | $11.08 | EPS 1Y | 1378.57% | EPS 3Y | -280.93% | EPS 5Y | -1422.93% |
| Sales QoQ | -12.16% | EPS QoQ | -1.51% | Sales QoQ Avg | 51.15% | EPS QoQ Avg | 63.23% |
| Gross Margin | 89.94% | Operating Margin | 28.81% | Profit Margin | 32.87% | ROCE | 17.67% |
| ROA | 17% | ROE | 22% | Altman Z Score | 22.2 | Piotroski Score | 5 |
| Current Ratio | 5.12 | Quick Ratio | 4.89 | Cash Ratio | 2.28 | Op. CF Ratio | 0.48 |
| Debt/Equity | 0.01 | Debt/Assets | 0 | Lt Debt/Equity | 0 | Lt Debt/Cap. | — |
| Intrst Cov. | 393.8 | Inventory Turnover | 1.41 | Asset Turnover | 0.52 | Receivables Turnover | 2.67 |
| Enterprise Value | $61.93B | P/E Ratio | 89.62 |
| Forward P/E | 22.36 | PEG Ratio | 0.09 |
| P/S Ratio | 13.2 | P/B Ratio | 8.13 |
| P/CF Ratio | 60.94 | P/FCF Ratio | 61.15 |
| EPS | $11.08 | EPS Growth 1Y | 1378.57% |
| EPS Growth 3Y | -280.93% | EPS Growth 5Y | -1422.93% |
| Revenue Growth 1Y | 140.81% | Gross Margin | 0.9% |
| Operating Margin | 0.29% | Profit Margin | 0.33% |
| ROE | 0.22% | ROA | 0.17% |
| ROCE | 0.18% | Current Ratio | 5.12 |
| Quick Ratio | 4.89 | Cash Ratio | 2.28 |
| Debt/Equity | 0.01 | Interest Coverage | 393.8 |
| Altman Z Score | 22.2 | Piotroski Score | 5 |
Argenx (ARGX) valuation & financials
Argenx (ARGX) has a market capitalization of $61.75B and trades at a price-to-earnings ratio of 89.6. It operates in the Healthcare sector (Biotechnology).
Argenx's revenue grew +140.8% over the last year.
Argenx's next earnings report is scheduled for March 4, 2027 before market open; analysts estimate EPS of $7.27. Check the earnings calendar to see all companies reporting this week.
Argenx (ARGX) — frequently asked questions
When does Argenx (ARGX) report earnings next?
Argenx is expected to report earnings on March 4, 2027 before market open. Analysts estimate EPS of $7.27.
What is Argenx's market cap?
Argenx (ARGX) has a market capitalization of $61.75B.
What is ARGX's P/E ratio?
Argenx trades at a price-to-earnings ratio of 89.6, with trailing twelve-month EPS of $11.08.
How fast is Argenx growing?
Argenx's revenue grew +140.8% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)